Most toddlers with severe RSV infections had no known health condition
Infections and vaccines after 50Part of a story we are following · 11 articles · See every update
Severe RSV infections in toddlers do not only happen to children with a known health problem. In a study of 574 children aged 8 to 23 months who were admitted to pediatric intensive care units with respiratory syncytial virus (RSV), about 6 in 10 had no preexisting health condition.
That can be hard to read if you have a little one at home. It is also useful to know. Severe illness in this age group was not limited to children who already had a medical label.
How the study worked
Researchers looked at children aged 8 to 23 months who were admitted to intensive care at 30 US children’s hospitals during the 2023 to 2024 and 2024 to 2025 RSV seasons. Every child tested positive for RSV and needed help breathing, from a nasal tube that delivers extra airflow up to a breathing machine. The results were published on November 2, 2026 in JAMA Network Open. Because the study only looked at children who were already in intensive care, it cannot tell us how likely any one child is to get this sick.
What they found
The team sorted the children into four groups based on their health history and on whether they met the US criteria for a second-season RSV antibody called nirsevimab.
- 47 children (8.2%) met the nirsevimab criteria.
- 76 children (13.2%) had other conditions known to raise the risk of severe RSV.
- 96 children (16.7%) had other health conditions.
- 355 children (61.8%) had no preexisting health conditions.
So the largest group by far was made up of children with no known condition.
The groups also differed in how sick the children became. Children who met the nirsevimab criteria were the most likely to need a breathing machine through a tube, which doctors call invasive mechanical ventilation.
| Group | Children who needed a breathing tube |
|---|---|
| Met nirsevimab criteria | 40.4% (19 of 47) |
| Other known RSV risk conditions | 17.1% (13 of 76) |
| Other health conditions | 10.4% (10 of 96) |
| No health conditions | 5.9% (21 of 355) |
In plain terms, about 4 in 10 children in the highest-risk group needed a breathing tube, compared with about 1 in 17 among children with no conditions. The pattern moved steadily from group to group, so more health conditions went along with more serious breathing support.
What is nirsevimab?
Nirsevimab is a monoclonal antibody. That means it is a lab-made protein that helps the body fight a specific virus, in this case RSV. In the US, it is recommended for certain high-risk children entering their second RSV season.
The researchers used the criteria recommended in August 2023 to sort the children. They say their findings might help inform future discussions about who should be eligible in a second season. That is a conversation for health officials. The study did not change any recommendation.
What does this mean for you?
Two things can be true at once. Among children already in intensive care with RSV, certain health conditions were linked to needing a breathing tube more often. And many of the children who ended up in intensive care had no known risk factor at all.
The study does not show that your child is in danger. It shows that the current eligibility criteria do not capture every child who gets severely ill. Researchers will keep studying that gap.
What you can do today
Current advice does not change because of this study. If your child is between 8 and 23 months old and has a long-term health condition, ask at your next pediatric visit whether they meet the criteria for nirsevimab in their second RSV season. If you are not sure whether a condition counts, the pediatrician can tell you.
For clinicians and researchers
Design: Cohort study of 574 US children aged 8 to 23 months admitted to the PICU at 30 pediatric hospitals in the 2023 to 2024 and 2024 to 2025 RSV seasons, all RSV-positive and on respiratory support. Four groups by nirsevimab eligibility and preexisting conditions.
Main result: Overall, 47 (8.2%) met nirsevimab eligibility criteria, 76 (13.2%) had other identified RSV risk conditions, 96 (16.7%) had other preexisting conditions, and 355 (61.8%) had none. Invasive mechanical ventilation: 40.4% (19 of 47) vs 17.1%, 10.4%, 5.9%; P for trend <.001.
Main limitation: Descriptive cohort restricted to PICU admissions with no non-admitted or healthy comparison group, so risk of severe RSV by condition cannot be estimated; no adjusted effect sizes are reported.
How it fits: Earlier Mongevity coverage of an RSV vaccine reported protection against infection and hospitalization; this study addresses a different question, which children in their second season reach intensive care. RSV vaccine showed strong protection against infections and hospital stays
Open question: Whether the second-season nirsevimab eligibility criteria should be revised, as the authors suggest, given that most PICU cases occurred in children without preexisting conditions.
Cite this article
Mongevity Desk. Most toddlers with severe RSV infections had no known health condition. Mongevity. Published November 22, 2026. Accessed November 22, 2026. https://mongevity.science/immunity/2026/11/severe-rsv-infections-toddlers-no-known-condition/Mongevity Desk. Most toddlers with severe RSV infections had no known health condition [Internet]. Mongevity; 2026 Nov 22 cited 2026 Nov 22]. Available from: https://mongevity.science/immunity/2026/11/severe-rsv-infections-toddlers-no-known-condition/Mongevity Desk. (2026, November 22). Most toddlers with severe RSV infections had no known health condition. Mongevity. https://mongevity.science/immunity/2026/11/severe-rsv-infections-toddlers-no-known-condition/
<a href="https://mongevity.science/immunity/2026/11/severe-rsv-infections-toddlers-no-known-condition/">Most toddlers with severe RSV infections had no known health condition</a>
Free to share or quote with credit and a link.
Questions and answers
- How many toddlers in the study had no known health condition?
- Of 574 children aged 8 to 23 months in intensive care with RSV, 355 (61.8%) had no preexisting health conditions.
- Who is recommended to get nirsevimab in a second RSV season?
- In the US, the antibody is recommended for certain high-risk children entering their second RSV season. The study used the criteria recommended in August 2023.
- Which children were most likely to need a breathing tube?
- Children who met the nirsevimab criteria. About 40.4% of them (19 of 47) needed a breathing tube, compared with 5.9% (21 of 355) of children with no health conditions.
- Does this study change the current advice for parents?
- No. The authors say the findings might inform future decisions about second-season eligibility, but current recommendations stay the same.





